PRC
ALLO icon

Pearl River Capital’s Allogene Therapeutics ALLO Stock Holding History

Pearl River Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,775
Closed -$204K – 348
2020
Q2 		$204K Buy
+4,775
New +$173K 0.1% 254
2019
Q3 		– Sell
-748
Closed -$20K – 415
2019
Q2 		$20K Buy
748
+558
+294% +$15.5K 0.13% 187
2019
Q1 		$6K Buy
+190
New +$5.51K 0.01% 318

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Pearl River Capital's ALLO Position: Q3 2020 in Review

Pearl River Capital sold out of Allogene Therapeutics (ALLO) in Q3 2020, closing a stake of 4,775 shares — an estimated $204K sold.

Pearl River Capital first reported a position in ALLO in Q1 2019 and held it in 3 quarters. The position peaked at $204K in Q2 2020. 162 funds tracked by Wall St. Rank hold ALLO as of Q3 2020.

  • Pearl River Capital reported no remaining Allogene Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Pearl River Capital sold 4,775 Allogene Therapeutics shares in Q3 2020, an estimated $204K.
  • Pearl River Capital first reported a position in Allogene Therapeutics in Q1 2019 and held it in 3 quarters.
  • Pearl River Capital's Allogene Therapeutics position peaked at $204K in Q2 2020.
  • 162 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2020.

Based on Pearl River Capital's 13F filing for Q3 2020, filed 13 Nov 2020.